Genovis Investor Relations Material
Latest events
Q1 2025
21 May, 2025
Q4 2024
14 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Genovis
Access all reports
Genovis develops and markets enzyme-based tools for the analysis and processing of biopharmaceutical products, especially therapeutic antibodies. Its products are used in research, development, and quality control laboratories. The company is headquartered in Lund, Sweden, and its shares are listed on the Nasdaq First North Growth Market.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GENO
Country
🇸🇪 Sweden